Journal article
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
Blood cancer journal (New York), Vol.15(1), 34
03/10/2025
DOI: 10.1038/s41408-025-01226-8
PMCID: PMC11893888
PMID: 40064854
Abstract
While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA-directed antibody-drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple myeloma (RRMM), eventually leading to its withdrawal from commercial use. With an imminent approval as an effective combination therapy, as seen in recent randomized trials, we report real-world clinical outcomes with belantamab mafodotin in 81 RRMM patients. With a median of 5 (range 2-15) prior lines of therapy, 92, 45, and 15% of the patients were triple-class refractory, penta-class refractory, and BCMA-refractory. More than half (57%) of the patients had high-risk cytogenetics, 37% had extramedullary disease (EMD), and 67% of the patients would have been considered ineligible for the DREAMM-2 trial. The best overall response (ORR) and complete response rates were 40.0 and 15.0%, respectively. ORRs were lower in patients with EMD, BCMA-refractory, and penta-refractory disease at 23, 17, and 24%, respectively. All-grade ocular toxicity was seen in 69% of patients, with grade 3+ events in 43%. Grade 3+ hematological toxicities included neutropenia (20%), anemia (28%), and thrombocytopenia (31%). With a median follow-up of 11.3 (0.3-44.6) months for the entire population, median PFS and OS were 5 (1-20) months and 12 (3-28) months, respectively. Presence of EMD was the only predictor of both PFS and OS on multivariable analysis. Compared to the pivotal trial and despite several high-risk disease features, belantamab mafodotin demonstrated comparable efficacy and safety in this real-world patient population.
Details
- Title: Subtitle
- A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
- Creators
- Rachel Dileo - Allegheny Health NetworkPrerna Mewawalla - Allegheny Health NetworkKalaivani Babu - Allegheny Health NetworkYue Yin - Allegheny-Singer Research InstituteChristopher Strouse - University of IowaEthan Chen - University of Iowa Hospitals and ClinicsHira Shaikh - University of IowaJames A Davis - Medical University of South CarolinaKimberly M Green - Medical University of South CarolinaOmar Alkharabsheh - USA Mitchell Cancer InstituteAliya Rashid - The University of Kansas Cancer CenterBidushi Pokhrel - The University of Kansas Cancer CenterNausheen Ahmed - The University of Kansas Cancer CenterAl-Ola Abdallah - The University of Kansas Cancer CenterHamza Hashmi - Memorial Sloan Kettering Cancer Center
- Resource Type
- Journal article
- Publication Details
- Blood cancer journal (New York), Vol.15(1), 34
- DOI
- 10.1038/s41408-025-01226-8
- PMID
- 40064854
- PMCID
- PMC11893888
- NLM abbreviation
- Blood Cancer J
- ISSN
- 2044-5385
- eISSN
- 2044-5385
- Publisher
- SPRINGERNATURE
- Language
- English
- Date published
- 03/10/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984800202702771
Metrics
53 Record Views